ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Dewpoint Therapeutics has launched with $60 million in its first formal round of funding, led by Polaris Partners, to translate new insights in biomolecular condensates into treatments. Membraneless organelles, called biomolecular condensates, help organize proteins and nucleic acids inside cells to allow certain critical chemical reactions to occur. The biotech firm, which has a long list of academic founders with expertise in physics, physical chemistry, and biology, will explore the role of these condensates in disease.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X